GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (CHIX:ARGXb) » Definitions » Net Policyholder Benefits/Claims

argenx SE (CHIX:ARGXB) Net Policyholder Benefits/Claims


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


argenx SE (CHIX:ARGXB) Business Description

Industry
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.